Leukemia

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

The FELIX trial demonstrated that obe-cel induced durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The combination of revumenib plus decitabine/cedazuridine showed high rates of remission among patients with relapsed/refractory AML with KMT2Ar, NPM1mt, and NUP98r genetic alterations.

Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.

Following risk management measures, ponatinib-associated adverse events in CML and ALL were shown to have decreased significantly since the drug’s approval.

Treatment with pirtobrutinib induced superior progression-free survival among heavily pretreated patients with relapsed or refractory CLL/SS previously treated with a covalent BTK inhibitor.

Secondary end points of the ASC4FIRST trial continue to show superior results with the use of asciminib, over standard-of-care TKIs in CML.

Treatment with acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over standard-of-care chemoimmunotherapy in patients with treatment-naive CLL.

Treatment with epcoritamab alone demonstrated deep responses in heavily pretreated patients with CLL, according to the expansion and optimization cohorts in the EPCORE CLL-1 trial.

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who were treated with revumenib, with no new safety signals found.

Treatment with bicistronic CD19/CD22-directed CAR T-cell therapy appeared safe and effective with high remission rates among children with relapsed/refractory B-ALL.

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in pediatric patients with standard-risk pediatric B-ALL.

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.

An expert discusses the FDA approval of obecabtagene autoleucel—the only CAR T-cell therapy given via split dosing for patients with ALL.

The FDA approved an oral solution of imatinib for multiple different cancer types.

The FDA approved an updated drug label for fludarabine phosphate for the treatment of B-cell chronic lymphocytic leukemia.

The FDA approved ninlotinib tablets that do not have mealtime restrictions for Ph-positive CML in chronic phase and CML that was previously treated.

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Brexu-cel is effective in treating patients with relapsed/refractory B-cell acute lymphoblastic leukemia, real-world data shows.

The FDA expanded the approval of methotrexate to include patients with pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.

The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.

The FDA granted a fast track designation to HC-7366 for adults with relapsed or refractory acute myeloid leukemia.

Asciminib is a promising agent for frontline chronic myeloid leukemia, Jorge Cortes, MD, explained.

Older adults with acute myeloid leukemia treated with anthracyclines tended to live longer, but also had more time spent in the hospital compared with those treated with HMAs.

Pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia are receiving tisagenlecleucel in earlier lines of therapy.

Minimal residual disease status was linked to progression-free survival in patients with chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Adding blinatumomab to consolidation chemotherapy provided a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

A fixed-duration treatment combining acalabrutinib and venetoclax, with or without obinutuzumab, significantly extended progression-free survival in patients with previously untreated chronic lymphocytic leukemia.

The FDA granted the investigational menin-MLL inhibitor DSP-5336 fast track designation for KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.